0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Recombinant Protein > Human Cell Expressed > Human Immunodeficiency Virus type 1 gp140 Protein

Human Immunodeficiency Virus type 1 gp140 Protein PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
11677-V02H
  YES          

Human Immunodeficiency Virus Type 1 gp140 Protein

 

HIV-1 gp140 Protein Price Inquiry ( Available Sizes )

HIV-1 gp140 Protein Product Information

Synonym :

gp140

Protein Construction:

A DNA sequence encoding the HIV-1 envelope glycoprotein gp160 extracellular domain ( Ala 29 - Ser 661 ), termed as gp140, was fused with the Fc region of human IgG1 at the C-terminus and a signal peptide at the N-terminus

Source:

Human Immunodeficiency Virus type 1 (HIV-1)

Strain : Similar to 97CN001
Expression Host: Human Cells

HIV-1 gp140 Protein QC Testing

Purity:

> 95 % as determined by SDS-PAGE

SDS-PAGE:
gp140 protein

gp140 protein

Bio-activity:

Using the Octet RED System , the affinity constant ( Kd ) of gp140-Fc bound to human CD4 is 0.3 μM
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Stability: Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal:

Ala 29

Molecular Mass: The recombinant HIV-1 gp140 consists of 874 amino acids after removal of the signal peptide and has a predicted molecular mass of 98 kDa. The apparent molecular mass of the recombinant protein is approximately 210 - 230 kDa in SDS-PAGE under reducing conditions
Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.

HIV-1 gp140 Protein Usage Guide

Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

HIV-1 gp140 Protein Related Products & Topics

Related Areas:

Virus Research Tools>>HIV-1 gp140

Proteins:

Antibodies:

HIV-1 gp140 Protein Description

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.
The HIV-1 envelope glycoprotein gp160, also known as Glycoprotein 160, is cleaved into two chains: the surface protein gp120 and the transmembrane protein gp41. The mature envelope protein (Env) consists of a homotrimer of non-covalently associated gp120-gp41 heterodimers. The surface protein gp120 attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Surface protein gp120 is a ligand for CD209 / DC-SIGN and CLEC4M / DC-SIGNR. It may target the virus to gut-associated lymphoid tissue (GALT) by binding host ITGA4/ITGB7 (alpha-4/beta-7 integrins), a complex that mediates T-cell migration to the GALT. The transmembrane protein gp41 (TM) acts as a class I viral fusion protein, and membranes fusion leads to delivery of the nucleocapsid into the cytoplasm. The external domains of the HIV-1 envelope glycoprotein (gp120 and the gp41 ectodomain, collectively known as gp140) contain all known viral neutralization epitopes.

References

  1. Robertson, DL. et al.,1995, J. Mol. Evol. 40 (3): 249-59.
  2. Gallo SA., et al., 2003, Biochim. Biophys. Acta. 1614: 36-50.
  3. Bobkov, AF. et al., 2004, J. Med. Virol. 74 (2): 191-6.
  4. Yang X., J. et al., 2005, Virol. 79: 12132-47.
  5. Beddows, S. et al., 2007, Virology. 360 (2): 329-40.
  6. Du, SX. et al., 2009, Virology. 395 (1): 33-44.
  7. Mendu, DR. et al., 2007, Biochem Biophys Res Commun. 363 (3): 466-71.